|
|
 |
Management Team
Executive Committee
Patrick
Soon-Shiong, M.D.
Executive Chairman
Abraxis BioScience
|
|
Dr. Soon-Shiong is the Executive Chairman and Chief Executive Officer of Abraxis Health. He was recently appointed Executive Director of the UCLA Wireless Health Institute, and is Professor of Microbiology, Immunology, and Molecular Genetics Professor of Bioengineering at UCLA.
Dr. Soon-Shiong holds a degree in Medicine from the University of the Witwatersrand, Johannesburg, South Africa, and a Master of Science from the University of British Columbia. He is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada. Dr. Soon-Shiong performed the world’s first encapsulated islet transplant in a diabetic patient. He developed the first FDA approved protein nanoparticle delivery technology for the treatment of metastatic breast cancer and this drug is being developed for lung, melanoma, gastric and pancreatic cancer. He is a co-inventor of over 50 issued U.S. patents, has published more than 100 scientific papers, and founder of 2 publicly traded pharmaceutical companies, American Pharma Partners and Abraxis Bioscience.
Dr. Soon-Shiong’s research has been recognized by national and international awards such as the Association for Academic Surgery Award for Research, the American College of Surgeons Schering Scholar, the Royal College Physicians and Surgeons Research Award, the Peter Kiewit Distinguished Membership in Medicine Award, and the International J.W. Hyatt Award for Service to Mankind. Dr. Soon-Shiong received the 2006 Gilda Club Award for the advancement of cancer medicine and is a recipient of a 2007 Ellis Island Medal of Honor as well as the St. Mary Medical Center Life Achievement Award in 2007 and the St. John’s Health Center Caritas Award in 2007.
In 2008 he received the Medical Visionary Award from the Pancreatic Cancer Action Network for his work in pancreatic cancer.
Dr. Soon-Shiong currently serves on the Board of Directors for the National Institute of Transplantation as well as the Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University which is part of the National Cancer Institute’s (NCI) five-year initiative for nanotechnology in cancer research. He also serves on two advisory boards for the RAND Corporation, the RAND Center for Asia Pacific Policy and the RAND Health Board of Advisors. Dr. Soon-Shiong recently joined the Board of Trustees for the Saint John’s Health Center in Los Angeles, California and the Advisory Board of the California NanoSystems Institute at UCLA. He also recently joined the Advisory Board for the Institute for Technology Advancement (ITA) at UCLA School of Engineering & Applied Science, as well as the Board of Councilors of the USC Viterbi School of Engineering.
In 2009 he was appointed to the President’s Council at RAND Corporation, Chairman of the Steering Committee of Life Sciences of the X-Prize Foundation and Founding Board member to Dossia Foundation.
Back to top
|
| |
|
|
Bruce
Wendel
Vice Chairman and Chief Executive Officer
Abraxis BioScience
|
|
Mr. Wendel became executive vice president of corporate development of Abraxis BioScience in May 2006. Mr. Wendel joined American Pharmaceutical Partners (APP) in 2004 as vice president of corporate development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. While at Bristol-Myers Squibb, as vice president, corporate development international medicines, he led teams that completed several major acquisitions, divestitures and alliances around the world. These transactions included a $225 million divestiture of Bristol's U.S. diagnostic division as well as the acquisition of three pharmaceutical firms in Argentina, South Korea, and Peru, and a co-promotion alliance with SmithKline Beecham for Avandia. Before joining APP, he served as vice president, business development and licensing for IVAX Corporation, a generic drug manufacturer, where late last year he completed the company's acquisition of 3M's European respiratory business. Previously, Mr. Wendel served in the legal departments of Playtex and Combe. He earned a Juris Doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.
Back to top |
| |
|
|
Mary Lynne Hedley, Ph.D.
Executive Vice-President and Chief Scientific Officer |
|
Dr. Hedley most recently served as Executive Vice President of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, INC. where she had served as Executive Vice President and Chief Scientific Officer since 2005. She joined MGI PHARMA in 2004 as Senior Vice President and General Manager. Previously, Dr. Hedley co-founded ZYCOS, Inc., a biotechnology company, and held roles of progressively greater responsibility ultimately leading to her serving as the company’s President and Chief Executive Officer. Dr. Hedley’s early research career consisted of two consecutive postdoctoral fellowships at Harvard University from 1989 through 1996. She earned her bachelor of science degree in Microbiology from Purdue University and her doctorate degree in Immunology from the University of Texas, Southwestern Medical Center. She is a named inventor on multiple patents in the field of immunology, and has been widely published in a variety of peer-reviewed journals. Dr. Hedley is the recipient of multiple awards and fellowships, is a frequent guest lecturer, and an active volunteer in educational as well as local community organizations. |
| |
|
|
Rick Rodgers
Senior Vice-President and Chief Financial Officer
|
|
Mr. Rodgers joined Abraxis BioScience in 2009. Previously, he was Senior Vice President, Controller and Chief Accounting Officer of MGI Pharma until the company’s acquisition by Eisai Corporation in 2008. In 2003, Mr. Rodgers was Corporate Controller of MedSource Technologies and from 1997 to 2002, he held various senior positions at ADC Telecommunications Inc. Prior to that, he held finance and accounting positions at several private and public companies. Mr. Rodgers began his financial career in accounting at Arthur Anderson & Co. Mr. Rodgers earned his bachelor of science degree in Financial Accounting from St. Cloud State University, Minn., and his master of business administration degree in Finance from the University of Minnesota, Carlson School of Business.
Back to top |
| |
|
|
Board of Directors
Patrick
Soon-Shiong, M.D.
Executive Chairman
Dr. Soon-Shiong is the Executive Chairman and Chief Executive Officer of Abraxis Health. He was recently appointed Executive Director of the UCLA Wireless Health Institute, and is Professor of Microbiology, Immunology, and Molecular Genetics Professor of Bioengineering at UCLA.
Dr. Soon-Shiong holds a degree in Medicine from the University of the Witwatersrand, Johannesburg, South Africa, and a Master of Science from the University of British Columbia. He is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada. Dr. Soon-Shiong performed the world’s first encapsulated islet transplant in a diabetic patient. He developed the first FDA approved protein nanoparticle delivery technology for the treatment of metastatic breast cancer and this drug is being developed for lung, melanoma, gastric and pancreatic cancer. He is a co-inventor of over 50 issued U.S. patents, has published more than 100 scientific papers, and founder of 2 publicly traded pharmaceutical companies, American Pharma Partners and Abraxis Bioscience .
Dr. Soon-Shiong’s research has been recognized by national and international awards such as the Association for Academic Surgery Award for Research, the American College of Surgeons Schering Scholar, the Royal College Physicians and Surgeons Research Award, the Peter Kiewit Distinguished Membership in Medicine Award, and the International J.W. Hyatt Award for Service to Mankind. Dr. Soon-Shiong received the 2006 Gilda Club Award for the advancement of cancer medicine and is a recipient of a 2007 Ellis Island Medal of Honor as well as the St. Mary Medical Center Life Achievement Award in 2007 and the St. John’s Health Center Caritas Award in 2007.
In 2008 he received the Medical Visionary Award from the Pancreatic Cancer Action Network for his work in pancreatic cancer.
Dr. Soon-Shiong currently serves on the Board of Directors for the National Institute of Transplantation as well as the Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University which is part of the National Cancer Institute’s (NCI) five-year initiative for nanotechnology in cancer research. He also serves on two advisory boards for the RAND Corporation, the RAND Center for Asia Pacific Policy and the RAND Health Board of Advisors. Dr. Soon-Shiong recently joined the Board of Trustees for the Saint John’s Health Center in Los Angeles, California and the Advisory Board of the California NanoSystems Institute at UCLA. He also recently joined the Advisory Board for the Institute for Technology Advancement (ITA) at UCLA School of Engineering & Applied Science, as well as the Board of Councilors of the USC Viterbi School of Engineering.
In 2009 he was appointed to the President’s Council at RAND Corporation, Chairman of the Steering Committee of Life Sciences of the X-Prize Foundation and Founding Board member to Dossia Foundation.
Back to top
Bruce Wendel
Vice Chairman and Chief Executive Officer
Mr. Wendel became executive vice president of corporate development of Abraxis BioScience in May 2006. Mr. Wendel joined American Pharmaceutical Partners (APP) in 2004 as vice president of corporate development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. While at Bristol-Myers Squibb, as vice president, corporate development international medicines, he led teams that completed several major acquisitions, divestitures and alliances around the world. These transactions included a $225 million divestiture of Bristol's U.S. diagnostic division as well as the acquisition of three pharmaceutical firms in Argentina, South Korea, and Peru, and a co-promotion alliance with SmithKline Beecham for Avandia. Before joining APP, he served as vice president, business development and licensing for IVAX Corporation, a generic drug manufacturer, where late last year he completed the company's acquisition of 3M's European respiratory business. Previously, Mr. Wendel served in the legal departments of Playtex and Combe. He earned a Juris Doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.
Back to top
Kirk
K. Calhoun
CPA, Retired , Ernst & Young, LLP Partner
Mr. Calhoun has served as a director since 2002. He joined Ernst & Young LLP in 1965
and served as a partner of the firm from 1975 until his retirement
in June 2002 where his responsibilities included both area management
and serving clients in a variety of industries. Mr. Calhoun is a
certified public accountant with a background in auditing and accounting.
Mr. Calhoun serves on the board of governors of the California State
University Foundation, serving as chairman from July 2000 to June
2003, and is a director of Myogen, Inc. Mr. Calhoun holds a B.S. in
accounting from the University of Southern California.
Back to top
David S. Chen,
Ph.D.
Cypac Investment Management
Dr. Chen has served as a director since June 1998. Dr. Chen was chairman of Cypac Investment Management Limited from 1998-2003. He served as chief executive officer of Central Investment Holdings Company from July 1996 to February 2000, and CFO from May 1991 to February 1994. Dr. Chen holds a B.S. in agricultural economics from National Taiwan University, a M.B.A. from California State University at Long Beach and a Ph.D. in business administration from Nova University, Florida.
Back to top
Stephen D. Nimer,
M.D.
Memorial Sloan Kettering Cancer Center
Dr. Nimer has served as director since May 2001.
Dr. Nimer has been associated with Memorial Sloan-Kettering Cancer
Center since 1993 and has been head of the division of hematologic
oncology since 1996 and chief of hematology service since 1993. He
has also taught medicine at the Cornell University School of Medicine
since 1993. Dr. Nimer holds a M.D. from the University of Chicago
and a B.S. in biology from Massachusetts Institute of Technology.
Back to top
Leonard Shapiro
Shapco, Inc.
Mr. Shapiro has served as a director since October 2002. He
has more than 50 years of business experience as an entrepreneur
and founder of Shapco, Inc., a manufacturer and distributor of pipe
products, where he has been the chief executive officer since 1948.
As chief executive officer of Shapco, he presided over the firm's
real estate investment activities in addition to its manufacturing
and distribution operations. Shapco, Inc., together with its subsidiaries,
employs over 300 employees in various locations throughout the western
United States.
Back to top
|
|
